EPRX

About Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) closed the 2026-09-16 session at $8.09, down 0.25% versus the previous close (-0.02). The stock opened at $8.12 and traded between $8.00 and $8.25 during that session. Session trading volume was 198K shares. The volume-weighted average price (VWAP) is $8.08.

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Eupraxia Pharmaceuticals Inc. Common Stock has a market capitalization of $535.9 million. EPRX is listed on the XNAS exchange. The company employs approximately 49 people. The recorded listing date is 2021-06-09.

On this page you can find market EPRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.